Abbvie (ABBV) Added to Conviction Buy List at Goldman Sachs; Analyst Sees 34% Upside
Tweet Send to a Friend
Goldman Sachs upgraded Abbvie (NYSE: ABBV) from Buy to Conviction Buy with a price target of $80.00 (from $76.00), suggesting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
